

## Prinomastat hydrochloride

## Chemical Properties


CAS No. : 1435779-45-5

Formula: C<sub>18</sub>H<sub>22</sub>ClN<sub>3</sub>O<sub>5</sub>S<sub>2</sub>

Molecular Weight: 459.97

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



## Biological Description

Description	Prinomastat hydrochloride is a orally active inhibitor of metalloproteinase (MMP)(MMP-1, MMP-3 and MMP-9 with IC <sub>50</sub> s of 79, 6.3 and 5.0 nM , respectively),with Antitumor avtivity.
Targets(IC <sub>50</sub> )	MMP
In vitro	Prinomastat inhibits Wnt1-induced MMP-3 production. Reversal of Wnt1-induced EMT and β-catenin transcriptional activity by Prinomastat[1].
In vivo	Prinomastat has good tumour growth inhibition, with a short T <sub>1/2</sub> of 1.6 hours[1].

## Solubility Information

Solubility	DMSO: 100 mg/mL (217.41 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1741 mL	10.8703 mL	21.7405 mL
5 mM	0.4348 mL	2.1741 mL	4.3481 mL
10 mM	0.2174 mL	1.087 mL	2.1741 mL
50 mM	0.0435 mL	0.2174 mL	0.4348 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

### Reference

- Sørensen MD, et al. Cyclic phosphinamides and phosphonamides, novel series of potent matrix metalloproteinase inhibitors with antitumour activity. *Bioorg Med Chem*. 2003 Dec 1;11(24):5461-84.
- Blavier L, et al. Stromelysin-1 (MMP-3) is a target and a regulator of Wnt1-induced epithelial-mesenchymal transition (EMT). *Cancer Biol Ther*. 2010 Jul 15;10(2):198-208.
- Shalinsky DR, et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. *Ann N Y Acad Sci*. 1999 Jun 30;878:236-70.
- Ozerdem U, et al. The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy. *Curr Eye Res*. 2000 Jun;20(6):447-53.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

**This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use**

Tel:781-999-4286    E\_mail:info@targetmol.com    Address:36 Washington Street,Wellesley Hills,MA 02481